|
04 Jun 2021 |
Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE, at 12th C1 Inhibitor Deficiency and Angioedema Workshop
|
|
04 Jun 2021 |
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC
|
|
04 Jun 2021 |
iTeos Therapeutics Announces New Phase 1/2a Data Indicating Antitumor Activity of inupadenant, its Adenosine A2A Receptor Antagonist, at ASCO 2021
|
|
04 Jun 2021 |
Constellation Pharmaceuticals Presents Phase 1 Data for CPI-0209 at ASCO Annual Meeting
|
|
04 Jun 2021 |
Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients
|
|
04 Jun 2021 |
Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat
|
|
04 Jun 2021 |
Yingli Pharma Announces presentations on the Phase 1 trials of linperlisib, a PI3Kδ selective inhibitor, and YL-13027, an oral TGFβR1 inhibitor, at the American Society for Clinical Oncology 2021 Annual Meeting
|
|
04 Jun 2021 |
Dermavant Submits New Drug Application (NDA) to FDA for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasis
|
|
04 Jun 2021 |
Alzheon Announces First Patient Dosed in APOLLOE4 Phase 3 Trial of Oral ALZ 801 in Patients with Early Alzheimer’s Disease
|
|
04 Jun 2021 |
Ribon Therapeutics Announces Oral Presentation of Positive Interim Data from Phase 1 Trial of RBN-2397 in Patients with Advanced Solid Tumors at 2021 ASCO Annual Meeting
|
|
04 Jun 2021 |
Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggressive Lymphomas and Advanced Solid Tumors
|
|
04 Jun 2021 |
Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera
|
|
04 Jun 2021 |
Lynparza reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial
|
|
04 Jun 2021 |
vasopharm Announces Results of the NOSTRA III Traumatic Brain Injury Phase III Study
|
|
03 Jun 2021 |
Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study
|
|
03 Jun 2021 |
United Therapeutics Announces First Patient Enrolled In Phase 3 TETON Study Of Tyvaso In Patients With Idiopathic Pulmonary Fibrosis
|
|
03 Jun 2021 |
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
|
|
02 Jun 2021 |
Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
|
|
02 Jun 2021 |
Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for BBT-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site
|
|
02 Jun 2021 |
AB Science announces a voluntary hold in the clinical studies of masitinib worldwide
|
|
01 Jun 2021 |
Sanofi provides update on venglustat clinical program
|
|
01 Jun 2021 |
NRx Pharmaceuticals Announces Positive Results for ZYESAMI™ (Aviptadil-acetate) and Submits Emergency Use Authorization Application to US Food and Drug Administration to Treat Critical COVID-19 in Patients Suffering from Respiratory Failure
|
|
01 Jun 2021 |
Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis
|
|
01 Jun 2021 |
Viracta Therapeutics Announces the Initiation of NAVAL-1, a Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma
|
|
01 Jun 2021 |
Mycovia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis
|
